NDATOPICALSHAMPOO
Approved
Oct 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
NIZORAL ANTI-DANDRUFF (ketoconazole) by Fabre-Kramer Pharmaceuticals is cytochrome p450 3a4 inhibitors [moa]. Approved for tinea pedis, seborrheic dermatitis, candidiasis, vulvovaginal and 1 more indications. First approved in 1997.
Drug data last refreshed 19h ago
Mechanism of Action
Cytochrome P450 3A4 Inhibitors
Pharmacologic Class:
Azole Antifungal
Indications (4)
Worked on NIZORAL ANTI-DANDRUFF at Fabre-Kramer Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.